SAPERCONAZOLE

Details

Stereochemistry	MIXED
Molecular Formula	C35H38F2N8O4
Molecular Weight	672.7242
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=CC=C(F)C=C7F)C=C4

InChI

InChIKey=HUADITLKOCMHSB-AVQIMAJZSA-N

InChI=1S/C35H38F2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C35H38F2N8O4
Molecular Weight	672.7242
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	2 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2090934 | https://www.ncbi.nlm.nih.gov/pubmed/1399205 | https://adisinsight.springer.com/drugs/800003602

Saperconazole, a N-1-substituted triazole antifungal that is a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus, and Trichophyton mentagrophytes. Saperconazole participated in a clinical trial for the treatment of mycoses. However, further, development was discontinued because of concerns about the possibility of drug-induced carcinogenesis.

Originator

Approval Year

PubMed

Title	Date	PubMed
Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B.	1994-02	8192469
Saperconazole therapy in a rabbit model of invasive aspergillosis.	1992-12	1482137
Saperconazole in the treatment of systemic and subcutaneous mycoses.	1992-10	1399205
Saperconazole: in vitro and in vivo anticandidal activity.	1992	1511634
Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes.	1990-07-01	2090934

Patents

Sample Use Guides

In Vivo Use Guide

In a 2-year period, 30 patients with culture-proven mycoses (chromoblastomycosis, sporotrichosis, and paracoccidioidomycosis) were treated with the new orally administered triazole, saperconazole (SPZ) (R66905). The daily dose varied from 100 to 200 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:16 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:16 GMT 2025`
Record UNII	R2I5PI29CA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAPERCONAZOLE

Official Name

English

R 66905

Preferred Name

English

SAPERCONAZOLE [MART.]

Common Name

English

R66,905

Code

English

R-66905

Code

English

R-66,905

Code

English

SAPERCONAZOLE [USAN]

Common Name

English

SAPERCONAZOLE [MI]

Common Name

English

saperconazole [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C514